You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 124 No. 6, June 1989 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL ARTICLES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on HighWire
 •Citing articles on Web of Science (17)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Thromboxane A2-Receptor Blockade and Prostacyclin in Porcine Escherichia coli Shock

Erik Svartholm, MD, PhD; David Bergqvist, MD; Ulla Hedner, MD, PhD; June Ljungberg; Ulf Haglund, MD, PhD

Arch Surg. 1989;124(6):669-672.


Abstract

• Septic shock was induced by intravenous infusion of live Escherichia coli in pigs to investigate the influences on central hemodynamic, coagulation, and fibrinolytic reactions by a thromboxane A2 (TxA2)–receptor blocker (BM 13.177; n=6) and a prostacyclin analogue (iloprost or ZK 36374; n=7). The early pulmonary vasoconstriction following E coli infusion was attenuated, but not abolished, by BM 13.177. Only minor effects were seen after pretreatment with iloprost. Neither drug had any major effect on the coagulation and fibrinolytic activation. These results confirm that TxA2 is an important, but not the only, mediator of early pulmonary vascular response in porcine septicemia and that neither TxA2 nor prostacyclin is of major importance for the hemostatic reactions in this shock model.

(Arch Surg 1989;124:669-672)



Author Affiliations

From the Departments of Surgery (Drs Svartholm, Bergqvist, and Haglund) and Experimental Research (Drs Svartholm, Bergqvist, Hedner, and Haglund, and Ms Ljungberg), Lund University, Malmö (Sweden) General Hospital; and Research Department, Novo Industri, A/S, Bagsvaerd, Denmark (Dr Hedner).


Footnotes

Accepted for publication July 15, 1988.

Reprint requests to Department of Surgery, University Hospital, S-751 85 Uppsala, Sweden (Dr Haglund).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Bosentan prevents hypoxia-reoxygenation-induced pulmonary hypertension and improves pulmonary function
Pearl et al.
Ann. Thorac. Surg. 1999;68:1714-1721.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1989 American Medical Association. All Rights Reserved.